ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update
A deeper dive into survodutide’s performance could undercut the GLP-1/glucagon drug’s competitiveness on raw weight loss and tolerability.
A deeper dive into survodutide’s performance could undercut the GLP-1/glucagon drug’s competitiveness on raw weight loss and tolerability.